<DOC>
	<DOC>NCT02113397</DOC>
	<brief_summary>The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous alternating therapy with TOBI™ Podhaler and colistimethate (Colistin).</brief_summary>
	<brief_title>Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>Diagnosis of cystic fibrosis confirmed by mutation analysis of the cystic fibrosis transmembrane conductance regulator gene Sputum or throat swab culture positive for Pseudomonas aeruginosa at or within 6 months of enrollment Age ≥12 years Forced expiratory volume in one second (FEV1) 2590 percentpredicted Age &lt;18 years Inability to routinely expectorate sputum without induction by hypertonic saline Inability to provide or withdrawal of written informed consent History of aminoglycoside sensitivity or adverse reaction to inhaled antibiotics Serum creatinine ≥ 2.0 mg/dl Serum blood urea nitrogen (BUN) ≥40 mg/dl Pregnancy or lactating at screening History of systemic intravenous antiPseudomonal antibiotics within 28 days of enrollment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Microbiome</keyword>
	<keyword>Sputum</keyword>
	<keyword>Tobramycin</keyword>
	<keyword>Colistimethate</keyword>
</DOC>